KR101615108B1 - 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법 - Google Patents

중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR101615108B1
KR101615108B1 KR1020127015676A KR20127015676A KR101615108B1 KR 101615108 B1 KR101615108 B1 KR 101615108B1 KR 1020127015676 A KR1020127015676 A KR 1020127015676A KR 20127015676 A KR20127015676 A KR 20127015676A KR 101615108 B1 KR101615108 B1 KR 101615108B1
Authority
KR
South Korea
Prior art keywords
delete delete
vomiting
palonosetron
nausea
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127015676A
Other languages
English (en)
Korean (ko)
Other versions
KR20120101456A (ko
Inventor
파비오 트렌토
세르기오 칸토레기
기오르기아 로시
로베르타 칸넬라
다니엘레 보나데오
리카르도 브라그리아
Original Assignee
헬신 헬스케어 에스.아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101615108(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 헬신 헬스케어 에스.아. filed Critical 헬신 헬스케어 에스.아.
Publication of KR20120101456A publication Critical patent/KR20120101456A/ko
Application granted granted Critical
Publication of KR101615108B1 publication Critical patent/KR101615108B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020127015676A 2009-11-18 2010-11-18 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법 Active KR101615108B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US61/262,470 2009-11-18
US38270910P 2010-09-14 2010-09-14
US61/382,709 2010-09-14

Publications (2)

Publication Number Publication Date
KR20120101456A KR20120101456A (ko) 2012-09-13
KR101615108B1 true KR101615108B1 (ko) 2016-05-12

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127015676A Active KR101615108B1 (ko) 2009-11-18 2010-11-18 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법

Country Status (40)

Country Link
US (1) US12042494B2 (https=)
EP (3) EP2727590B1 (https=)
JP (1) JP5890780B2 (https=)
KR (1) KR101615108B1 (https=)
CN (6) CN106421793B (https=)
AP (1) AP3083A (https=)
AU (1) AU2010320598B2 (https=)
BR (1) BR112012011485B1 (https=)
CA (1) CA2778301C (https=)
CL (1) CL2012001276A1 (https=)
CO (1) CO6551693A2 (https=)
CR (1) CR20120216A (https=)
CU (1) CU24048B1 (https=)
CY (1) CY1118062T1 (https=)
DK (2) DK2361090T3 (https=)
DO (1) DOP2012000138A (https=)
EA (1) EA026815B1 (https=)
EC (1) ECSP12011907A (https=)
ES (4) ES2623503T3 (https=)
GE (1) GEP20156226B (https=)
GT (1) GT201200156A (https=)
HK (2) HK1214148A1 (https=)
HR (3) HRP20140759T1 (https=)
HU (1) HUE029677T2 (https=)
IL (1) IL219576A (https=)
LT (1) LT2722045T (https=)
MA (1) MA33810B1 (https=)
MX (1) MX2012005347A (https=)
MY (1) MY159393A (https=)
NI (1) NI201200090A (https=)
NZ (1) NZ599439A (https=)
PE (1) PE20121483A1 (https=)
PH (1) PH12012500887A1 (https=)
PL (3) PL2361090T3 (https=)
PT (2) PT2361090E (https=)
RS (2) RS55206B1 (https=)
SI (2) SI2361090T1 (https=)
SM (1) SMT201400112B (https=)
TN (1) TN2012000170A1 (https=)
WO (1) WO2011061622A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2013004766A1 (en) * 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
CN105412110B (zh) * 2011-10-18 2018-05-25 赫尔森保健股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
EP3746078A4 (en) * 2018-02-02 2021-11-17 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) ORAL FORMULATIONS AND USES THEREOF
AU2021407138A1 (en) * 2020-12-25 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4633608A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2025246530A1 (en) * 2024-05-30 2025-12-04 The Chinese University Of Hong Kong Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL166267B1 (pl) 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych zwiazków trójpierscieniowych PL PL PL PL
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
MXPA03000366A (es) 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
JP4116436B2 (ja) 2000-12-14 2008-07-09 エフ．ホフマン−ラ ロシュ アーゲー 自己乳化脂質マトリックス（ｓｅｌｍ）
DE10393729T5 (de) 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007096763A2 (en) 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
KR101441459B1 (ko) 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
JP2011505873A (ja) * 2007-12-18 2011-03-03 シェーリング コーポレイション 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Supportive Cancer Therapy, 2006, Vol.3(3), pages 140-142*

Also Published As

Publication number Publication date
AU2010320598B2 (en) 2016-06-16
PT2361090E (pt) 2014-09-03
ES2623503T3 (es) 2017-07-11
CN106512010A (zh) 2017-03-22
EP2727590B1 (en) 2015-10-21
CN106421793A (zh) 2017-02-22
HUE029677T2 (hu) 2017-03-28
AP2012006278A0 (en) 2012-06-30
HK1214148A1 (zh) 2016-07-22
SI2722045T1 (sl) 2017-02-28
MY159393A (en) 2016-12-30
ECSP12011907A (es) 2012-10-30
EA026815B1 (ru) 2017-05-31
DOP2012000138A (es) 2012-11-15
PT2722045T (pt) 2016-10-18
EP2361090A1 (en) 2011-08-31
MA33810B1 (fr) 2012-12-03
AU2010320598A1 (en) 2012-06-14
CN106421793B (zh) 2023-06-16
ES2595077T3 (es) 2016-12-27
US12042494B2 (en) 2024-07-23
RS55206B1 (sr) 2017-01-31
GEP20156226B (en) 2015-01-26
IL219576A0 (en) 2012-06-28
CN102655864A (zh) 2012-09-05
CU24048B1 (es) 2014-12-26
IL219576A (en) 2017-08-31
WO2011061622A1 (en) 2011-05-26
ES2494015T3 (es) 2014-09-12
PL2722044T3 (pl) 2017-08-31
DK2361090T3 (da) 2014-08-25
DK2722045T3 (en) 2016-10-24
LT2722045T (lt) 2016-09-26
PL2722045T3 (pl) 2017-03-31
PL2361090T3 (pl) 2014-10-31
PE20121483A1 (es) 2012-12-02
HRP20140759T1 (hr) 2014-10-24
CA2778301A1 (en) 2011-05-26
CA2778301C (en) 2016-06-14
CO6551693A2 (es) 2012-10-31
CL2012001276A1 (es) 2012-12-07
HRP20161277T1 (hr) 2016-11-18
BR112012011485B1 (pt) 2021-06-29
EP2722044A1 (en) 2014-04-23
MX2012005347A (es) 2012-08-03
RS53491B1 (sr) 2015-02-27
CN107050455A (zh) 2017-08-18
JP5890780B2 (ja) 2016-03-22
EP2727590A1 (en) 2014-05-07
KR20120101456A (ko) 2012-09-13
JP2013511507A (ja) 2013-04-04
GT201200156A (es) 2014-03-27
CR20120216A (es) 2012-07-24
CU20120078A7 (es) 2012-10-15
BR112012011485A2 (pt) 2018-04-03
CN107050455B (zh) 2020-09-29
SI2361090T1 (sl) 2014-09-30
AP3083A (en) 2015-01-31
PH12012500887A1 (en) 2016-08-26
CN104856998A (zh) 2015-08-26
EP2722044B1 (en) 2017-01-04
EA201290356A1 (ru) 2012-12-28
ES2559475T3 (es) 2016-02-12
NZ599439A (en) 2014-06-27
HK1214147A1 (zh) 2016-07-22
CN104856999A (zh) 2015-08-26
SMT201400112B (it) 2014-11-10
CY1118062T1 (el) 2017-06-28
TN2012000170A1 (en) 2013-12-12
US20230263799A1 (en) 2023-08-24
HRP20170419T1 (hr) 2017-06-02
NI201200090A (es) 2012-11-13
EP2361090B1 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
KR101615108B1 (ko) 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법
US11559523B2 (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1228787A1 (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1171391A (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1228787B (en) Compositions and methods for treating centrally mediated nausea and vomiting

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 10, Claim Number : 1, 2, 3, 4, 5, 6, 7, 8, 9 10, Period Limitation Text : 337, Comment Text : 36

FPAY Annual fee payment

Payment date: 20190401

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20200401

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 10, Claim Number : 1, 2, 3, 4, 5, 6, 7, 8, 9 10, Period Limitation Text : 337, Comment Text : 36

FPAY Annual fee payment

Payment date: 20210329

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20220324

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11